EGFR and hepatocellular carcinoma: Subsequent phase I clinical trials demonstrated a strong synergistic effect of lenvatinib in combination with the EGFR inhibitor gefitinib in advanced HCC with high expression of EGFR and refractory to lenvatinib mono-therapy, with 9 out of 30 cases achieving partial response (NCT04642547).